- Wednesday's Economic News Crunch Could Tilt Markets
- Call Me Crazy: Confessions of a Black Friday Shopper
- US Firms Hit by Payroll Taxes at Exactly the Wrong Time
- Citi Mortgage Reveals Something the US Treasury Won't
- Fed Sanguine About US Recovery, Worried on Jobs
- Amended Berkshire Filing Reveals No 'Secret' Holdings
- In Time for Holidays: More Gloom and Doom on Economy
- Holiday Guide to This Season's Smartphones
- Market Pros Reveal Top Black Friday Trades
- Citi Mortgage Reveals What Treasury Won't
- S&P to Hit 1,200 by Year-End: Chief Investor
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- Facebook's Biggest-Ever Holiday Shopping Season
- Facebook's New Dual Class Structure - Slow Steps to an IPO
- 5 Big Bank Stocks Investors Should Consider: Strategists
- Gambling Drunk, Texting to Live And America's On Sale - Your Emails
- Nov. 24: Unusual Volume Leaders
- NBA D-League On The Rise
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- Wednesday's Economic News Crunch Could Tilt Markets
- NBA D-League On The Rise
- Japan Export Rebound Eases Fear of New Recession
- CNBC Anchor Takes a Sabbatical
- Citi Mortgage Reveals What Treasury Won't
- Rethinking Work
- Madoff—The Holiday Drink
- China Shipbuilding to Launch $937 Million China IPO
Text Size 
Invitrogen plans to buy Applied Biosystems in a deal valued at $6.7 billion to form a massive provider of research tools for the life sciences industry, the companies said on Thursday.
The purchase price of $38 per share in cash and stock represents a premium of 17 percent over Applied Biosystems' closing price on Wednesday and 12 percent over its average closing price over the past 30 days. The split is expected to be 45 percent cash and 55 percent Invitrogen stock.
The combined company will generate about $3.5 billion in combined sales, offering a wide variety of products in areas such as genetic analysis, proteomics, cell biology and cell systems.
Applied Biosystems' equipment includes mass spectrometers, which can measure the molecular weight of proteins and thereby identify them.
Invitrogen [IVGN
Loading...
()
] shares fell 10 percent after the deal announcement, while Applied Biosystems [ABI
Loading...
()
] rose 8 percent.
"In the most general terms, it makes sense in terms of their expertise in molecular biology, efficiencies in combined sales forces, overlap on product line and intellectual property interests," said Deutsche Bank analyst Ross Muken. Such a combination was a source of speculation at a conference in Denver last week, he added.
Upon closing, Invitrogen shareholders would own the majority of the merged company, which would be named Applied Biosystems.
Applied Biosystems is one of two tracking stocks of Applera, which announced the deal with Invitrogen. Celera Group [CRA
Loading...
()
] is the other.
The companies expect the merger to close in the fall and to be neutral to or slightly help earnings per share in the first year and significantly positive in the second year.
Invitrogen shares fell $4.35 to $39 in early electronic trading from a Wednesday close of $43.35 on Nasdaq.
Applied Biosystems shares rose to $35 from Wednesday's New York Stock Exchange close of $32.44.
Print
Email
- Remember when auto shows were major events where new models could generate buzz?
- CNBC’s Mike Huckman visits a cutting-edge plant to see how the flu vaccine of the future is being made.
- People who bottle up their anger at work are up to five times more likely to suffer a heart attack, a study found.
- Playboy will outsource its publishing operations in a bid to become profitable again.
- A new McDonald's in Manhattan is the nation's first to sport a sleek, chic interior imported from stores in London and Paris.
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
Data is a real-time snapshot *Data is delayed at least 15 minutes